Clinical research progresses in umbilical cord blood transplantation in the treatment of hematologic malignancies
10.3969/j.issn.1007-3969.2014.10.003
- VernacularTitle:脐血移植治疗血液系统恶性疾病的临床研究进展
- Author:
Liyuan MA
;
Siguo HAO
- Publication Type:Journal Article
- Keywords:
Hematopoietic stem cell transplantation;
Umbilical cord blood;
Hematologic malignancies
- From:China Oncology
2014;(10):732-737
- CountryChina
- Language:Chinese
-
Abstract:
Allogeneic hematopoietic stem cell transplantation is the only treatment method to cure hemato-logic malignancies. However, dififculty in obtaining the human leukocyte antigen (HLA) match donors is a major lim-itation in this therapeutic strategy. Many studies have demonstrated that umbilical cord blood is rich in hematopoietic stem cells and can be used as a source of stem cells of hematopoietic stem cell transplantation. Growing evidence also supports the efifcacy of cord blood transplantation (CBT) to treat patients with haematological malignancies, and the number of CBTs is rapidly increasing. Compared to other sources of stem cells, umbilical cord blood is physical cryo-preserved. Therefore, it is very convenient for transplantation, particular for those who need to receive transplantation sooner. In addition, the incidence and severity of graft versus host disease(GVHD) in CBT are usually relatively lower. Herein, we review considerations regarding status, research progresses and selection of umbilical cord blood in CBT.
